-+ 0.00%
-+ 0.00%
-+ 0.00%
AcuCort Files for FDA Approval of Zeqmelit
Share
Listen to the news
AcuCort Files for FDA Approval of Zeqmelit
  • AcuCort submitted a new drug application to the FDA seeking US marketing approval for Zeqmelit through the 505(b)(2) pathway.
  • An FDA small-business waiver granted in July 2026 exempts the company from an application fee of about SEK 22 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AcuCort AB published the original content used to generate this news brief via Cision (Ref. ID: 202611160230BITN____UKPR__SV_20261115-BIT-9356-0) on November 16, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending